Physician profile
Fanny E Ramirez
NPI 1881796076
$3,031.06
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $955.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.83 | 2019-2020 | |
| Amarin Pharma, INC. | $398.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $372.97 | 2019-2020 | |
| Novo Nordisk INC | $367.13 | 2019-2020 | |
| Lilly USA, LLC | $233.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $153.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $147.50 | 2019-2020 | |
| Glaxosmithkline, LLC. | $143.83 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $125.79 | 2019-2020 | |
| Allergan, INC. | $119.35 | 2019-2020 | |
| Pfizer INC. | $114.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $83.80 | 2019-2020 | |
| Boston Scientific Corporation | $74.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.46 | 2019-2020 | |
| Astellas Pharma US INC | $66.19 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $49.42 | 2019-2020 | |
| Amgen INC. | $42.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.20 | 2020 | |
| Shire North American Group INC | $18.75 | 2019 | |
| Strongbridge US INC. | $16.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fanny Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.